Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD

Yan Xie(Beijing University of Posts and Telecommunications), Ziyad Al‐Aly(Washington University in St. Louis), Tingting Li(Wenzhou Medical University), Hong Xian(VA St. Louis Health Care System), Benjamin Bowe(Washington University in St. Louis), Sumitra Balasubramanian(VA St. Louis Health Care System)
Journal of the American Society of Nephrology
March 14, 2016
10.1681/asn.2015121377
Cited by 337

Related Papers

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2018|14k
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|13.5k
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2018|8.7k
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|4.9k
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet|2024|4.4k